REFERENCES
  1. Cabral BMI, Edding SN, Portocarrero JP, Lerma EV. Rhabdomyolysis. Dis Mon. 2020 Aug;66(8):101015. doi: 10.1016/j.disamonth.2020.101015.
  2. Khan Z, Karataş Y, Kıroğlu O. Evaluation of Adverse Drug Reactions in Paediatric Patients: A Retrospective Study in Turkish Hospital. Front Pharmacol. 2021;12:786182. doi: 10.3389/fphar.2021.786182.
  3. Papakonstantinou C, Papanastasiou K, Kotsopoulou M, Mouratidou M, Sotiropoulos D, Kyrtsoni MC, Pouli A, Stamatelou M, Maniatis A. Chemotherapy-related acute rhabdomyolysis. J Natl Cancer Inst. 1992 Apr 1;84(7):536-7.
  4. Levy RJ, Sparano JA, Khan G. Rhabdomyolysis: an unusual complication of cytotoxic chemotherapy. Med Oncol. 1995 Dec;12(4):219-22. doi: 10.1007/BF02990567.
  5. Anderlini P, Buzaid AC, Legha SS. Acute rhabdomyolysis after concurrent administration of interleukin-2, interferon-alfa, and chemotherapy for metastatic melanoma. Cancer. 1995 Aug 15;76(4):678-9. doi: 10.1002/1097-0142(19950815)76:4<678::aid-cncr2820760422>3.0.co;2-q.
  6. Hoshi S, Itoh A, Kato S, Suzuki K, Kawamura S, Orikasa S. Severe rhabdomyolysis as a complication of high-dose chemotherapy in a patient with advanced testicular cancer. Int J Urol. 1999 Jan;6(1):56-8. doi: 10.1046/j.1442-2042.1999.06130.x.
  7. Shima E, Hino M, Yamane T, Aoyama Y, Nakamae H, Yamamura R, Makita K, Sugano Y, Yasuda S, Takubo T, Ohta K, Tatsumi N. Acute rhabdomyolysis following administration of high-dose cyclophosphamide: case report. Ann Hematol. 2002 Jan;81(1):55-6. doi: 10.1007/s00277-001-0399-2.
  8. Truica, C. I., & Frankel, S. R. (2002). Acute rhabdomyolysis as a complication of cytarabine chemotherapy for acute myeloid leukemia: case report and review of literature. Am J Hematol , 70, 320-323. doi: 10.1002/ajh.10152
  9. Truica CI, Frankel SR. Acute rhabdomyolysis as a complication of cytarabine chemotherapy for acute myeloid leukemia: case report and review of literature. Am J Hematol. 2002 Aug;70(4):320-3. doi: 10.1002/ajh.10152.
  10. Ceribelli A, Cecere FL, Milella M, Facciolo F, Gelibter A, Cognetti F. Severe rhabdomyolysis associated with pemetrexed-based chemotherapy. Lancet Oncol. 2006 Apr;7(4):353. doi: 10.1016/S1470-2045(06)70662-3.
  11. Ramamoorthy SK, Marangolo M, Durrant E, Akima S, Gottlieb DJ. Unusual reaction to Rituximab with intra-vascular hemolysis, rhabdomyolysis, renal failure and bone marrow necrosis. Leuk Lymphoma. 2006 Apr;47(4):747-50.
  12. Penel N, Blay JY, Adenis A. Imatinib as a possible cause of severe rhabdomyolysis. N Engl J Med. 2008 Jun 19;358(25):2746-7. doi: 10.1056/NEJMc0708896.
  13. Veeraputhiran M, Sundermeyer M. Rhabdomyolysis resulting from pharmacologic interaction between erlotinib and simvastatin. Clin Lung Cancer. 2008 Jul;9(4):232-4. doi: 10.3816/CLC.2008.n.036.
  14. Vicente E, Zafra M, Garcia-Martinez E, de la Peña FA. Acute rhabdomyolysis as a complication of paclitaxel-gemcitabine chemotherapy for ovarian cancer. Eur J Obstet Gynecol Reprod Biol. 2009 Aug;145(2):226. doi: 10.1016/j.ejogrb.2009.04.029.
  15. Urata C, Yoshimura M, Itamura H, Hisatomi T, Kubota Y, Fukushima N, Sueoka E, Kimura S. Lenalidomide in combination with dexamethasone induced rhabdomyolysis in a multiple myeloma patient treated with pravastatin. Int J Hematol. 2011 Aug;94(2):216-217. doi: 10.1007/s12185-011-0903-y.
  16. Moscetti L, Nelli F, Ruggeri EM. Rhabdomyolysis from erlotinib: a case report. Tumori. 2011 May-Jun;97(3):415-6. doi: 10.1700/912.10044.
  17. Huang MS, Tsai JR, Shen MC, Chou SH, Yang CJ. Pemetrexed as a possible cause of severe rhabdomyolysis in the treatment of lung cancer. Lung Cancer. 2012 Jun;76(3):491-2. doi: 10.1016/j.lungcan.2012.02.009.
  18. Sobol G, Musioł K, Mizia-Malarz A, Stolpa W, Krupa M, Woś H. Rhabdomyolysis: rare complications with a difficult prognosis in the course of anticancer treatment. J Pediatr Hematol Oncol. 2012 May;34(4):e142-4. doi: 10.1097/MPH.0b013e318236b2fd.
  19. Matsuzaki H, Koga Y, Suminoe A, Oba U, Takimoto T, Hara T. Severe acute rhabdomyolysis induced by multi-agent chemotherapy for alveolar rhabdomyosarcoma in a 15-year-old female: a case report. Case Rep Oncol. 2013 Jul 31;6(2):397-402. doi: 10.1159/000354271.
  20. Gavigan G, McEvoy A, Young V. Acute rhabdomyolysis as a complication of interferon treatment for stage IIIc melanoma. J Cutan Med Surg. 2014 Jul-Aug;18(4):277-9. doi: 10.2310/7750.2013.13115.
  21. Min L, Hodi FS. Anti-PD1 following ipilimumab for mucosal melanoma: durable tumor response associated with severe hypothyroidism and rhabdomyolysis. Cancer Immunol Res. 2014 Jan;2(1):15-8. doi: 10.1158/2326-6066.CIR-13-0146.
  22. Hong YA, Kim HD, Jo K, Park YK, Lee J, Sun IO, Chung BH, Park CW, Yang CW, Choi BS. Severe rhabdomyolysis associated with concurrent use of simvastatin and sirolimus after cisplatin-based chemotherapy in a kidney transplant recipient. Exp Clin Transplant. 2014 Apr;12(2):152-5. doi: 10.6002/ect.2013.0003.
  23. Koršić M, Muršić D, Badovinac S, Božina N, Roglić M, Jakopović M, Čučević B. Erlotinib-related rhabdomyolysis: the role of pharmacogenetics and drug-drug interaction. Cancer Chemother Pharmacol. 2015 Dec;76(6):1317-9. doi: 10.1007/s00280-015-2885-6.
  24. Neyra JA, Rocha NA, Bhargava R, Vaidya OU, Hendricks AR, Rodan AR. Rhabdomyolysis-induced acute kidney injury in a cancer patient exposed to denosumab and abiraterone: a case report. BMC Nephrol. 2015 Jul 30;16:118. doi: 10.1186/s12882-015-0113-6.
  25. Sakai K, Mochizuki H, Mochida K, Shiomi K, Amano M, Nakazato M. A Case of Nivolumab-Induced Severe Mononeuropathy Multiplex and Rhabdomyolysis. Case Rep Med. 2017;2017:1093858. doi: 10.1155/2017/1093858.
  26. He H, An R, Hou J, Fu W. Arsenic trioxide induced rhabdomyolysis, a rare but severe side effect, in an APL patient: a case report. Front Med. 2017 Jun;11(2):284-286. doi: 10.1007/s11684-017-0514-y.
  27. Sokolova A, Chan O, Ullah W, Hamdani AA, Anwer F. Delayed rhabdomyolysis with paclitaxel, ifosfamide, carboplatin, and etoposide regimen: a case report. J Med Case Rep. 2017 Apr 11;11(1):100. doi: 10.1186/s13256-017-1272-9.
  28. Logue JM, Kiani B, Bitting RL. Pazopanib and Statin-Induced Rhabdomyolysis. Case Rep Oncol. 2017 Oct 31;10(3):954-957. doi: 10.1159/000481659.
  29. Hamada S, Fuseya Y, Tsukino M. Pembrolizumab-Induced Rhabdomyolysis With Myositis in a Patient With Lung Adenocarcinoma. Arch Bronconeumol (Engl Ed). 2018 Jun;54(6):346-348. English, Spanish. doi: 10.1016/j.arbres.2018.01.026.
  30. Damato A, Larocca M, Rondini E, Menga M, Pinto C, Versari A. Severe Rhabdomyolysis during Treatment with Trabectedin in Combination with a Herbal Drug in a Patient with Metastatic Synovial Sarcoma: A Case Report. Case Rep Oncol. 2017 Mar 28;10(1):258-264. doi: 10.1159/000464440.
  31. Chen Q, Huang DS, Zhang LW, Li YQ, Wang HW, Liu HB. Fatal myocarditis and rhabdomyolysis induced by nivolumab during the treatment of type B3 thymoma. Clin Toxicol (Phila). 2018 Jul;56(7):667-671. doi: 10.1080/15563650.2017.1401079.
  32. Sullivan K, Lee CS. Pemetrexed-induced severe rhabdomyolysis in lung cancer: A case report. J Oncol Pharm Pract. 2019 Dec;25(8):2007-2009. doi: 10.1177/1078155218816767.
  33. Clark JI, Bufalino S, Singh S, Borys E. Rhabdomyolysis during high dose interleukin-2 treatment of metastatic melanoma after sequential immunotherapies: a case report. J Immunother Cancer. 2018 Jun 14;6(1):53. doi: 10.1186/s40425-018-0370-6.
  34. Dineen M, Hansen E, Guancial E, Sievert L, Sahasrabudhe D. Abiraterone-induced rhabdomyolysis resulting in acute kidney injury: A case report and review of the literature. J Oncol Pharm Pract. 2018 Jun;24(4):314-318. doi: 10.1177/1078155217701294.
  35. Muto Y, Ng W, Namikawa K, Takahashi A, Tsutsumida A, Nishida M, Yamazaki N. Success of rechallenging dabrafenib and trametinib combination therapy after trametinib-induced rhabdomyolysis: a case report. Melanoma Res. 2018 Apr;28(2):151-154. doi: 10.1097/CMR.0000000000000424.
  36. Pourhassan HZ, Tryon D, Schaeffer B, Mirshahidi H, Wong J. Autoimmune rhabdomyolysis and a multiorgan display of PD-1 inhibitor induced immune related adverse events during treatment of metastatic melanoma. Exp Hematol Oncol. 2019 Sep 10;8:20. doi: 10.1186/s40164-019-0140-2.
  37. Irimada, M., Fujimura, T., Kambayashi, Y., Tsukada, A., Takahashi, T., Hashimoto, A.,… Aiba, S. (2019). Severe rhabdomyolysis developing in an advanced melanoma patient treated by pembrolizumab followed by dabrafenib trametinib combined therapy. J Dermatol , 46, e256-e258. doi: 10.1111/1346-8138.14778
  38. Irimada M, Fujimura T, Kambayashi Y, Tsukada A, Takahashi T, Hashimoto A, Aiba S. Severe rhabdomyolysis developing in an advanced melanoma patient treated by pembrolizumab followed by dabrafenib trametinib combined therapy. J Dermatol. 2019 Jul;46(7):e256-e258. doi: 10.1111/1346-8138.14778.
  39. Thalambedu N, Atiq MU, Patel S. A Case of Docetaxel-Induced Rhabdomyolysis. Cureus. 2020 Jul 25;12(7):e9380. doi: 10.7759/cureus.9380.
  40. Díaz Alcázar MDM, Cervilla Sáez de Tejada E, Ruiz Escolano E. Rhabdomyolysis in a patient under treatment with sorafenib. Rev Esp Enferm Dig. 2020 Mar;112(3):243-244. doi: 10.17235/reed.2020.6440/2019.
  41. Adachi Y, Yanagimura N, Suzuki C, Ootani S, Tanimoto A, Nishiyama A, Yamashita K, Ohtsubo K, Takeuchi S, Yano S. Reduced doses of dabrafenib and trametinib combination therapy for BRAF V600E-mutant non-small cell lung cancer prevent rhabdomyolysis and maintain tumor shrinkage: a case report. BMC Cancer. 2020 Feb 24;20(1):156. doi: 10.1186/s12885-020-6626-9.
  42. Finsterer J. Trametinib and dabrafenib induced rhabdomyolysis, renal failure, and visual loss. Report of one case. Rev Med Chil. 2020 Nov;148(11):1684-1689. doi: 10.4067/S0034-98872020001101684.
  43. Abushalha K, Abulaimoun S, Silberstein PT. So slow, so fast, a case of nivolumab-induced hypothyroidism with subsequent rhabdomyolysis. Immunotherapy. 2020 Jun;12(9):625-628. doi: 10.2217/imt-2020-0053.
  44. Ould-Nana I, Cillis M, Gizzi M, Gillion V, Hantson P, Gérard L. Rhabdomyolysis and acute kidney injury induced by the association of rosuvastatin and abiraterone: A case report and review of the literature. J Oncol Pharm Pract. 2021 Jan;27(1):216-219. doi: 10.1177/1078155220923001.
  45. Khan T, Gurav P. PhytoNanotechnology: Enhancing Delivery of Plant Based Anti-cancer Drugs. Front Pharmacol. 2018 Feb 9;8:1002. doi: 10.3389/fphar.2017.01002.
  46. Zhou J, Kang Y, Chen L, Wang H, Liu J, Zeng S, Yu L. The Drug-Resistance Mechanisms of Five Platinum-Based Antitumor Agents. Front Pharmacol. 2020 Mar 20;11:343. doi: 10.3389/fphar.2020.00343.
  47. Ge L, Li N, Yuan GW, Sun YC, Wu LY. Nedaplatin and paclitaxel compared with carboplatin and paclitaxel for patients with platinum-sensitive recurrent ovarian cancer. Am J Cancer Res. 2018 Jun 1;8(6):1074-1082.
  48. Wang H, Zhu X, Huang J, Chen P, Han S, Yan X. Nedaplatin sensitization of cisplatin-resistant human non-small cell lung cancer cells. Oncol Lett. 2016 Apr;11(4):2566-2572. doi: 10.3892/ol.2016.4276.
  49. Yang JJ, Zhou Q, Liao RQ, Huang YS, Xu CR, Wang Z, Wang BC, Chen HJ, Wu YL. Nedaplatin/Gemcitabine Versus Carboplatin/Gemcitabine in Treatment of Advanced Non-small Cell Lung Cancer: A Randomized Clinical Trial. Chin J Cancer Res. 2012 Jun;24(2):97-102. doi: 10.1007/s11670-012-0097-8.
  50. Zhang K, Qin H, Pan F, Liu E, Liang H, Ruan Z. Nedaplatin or oxaliplatin combined with paclitaxel and docetaxel as first-line treatment for patients with advanced non-small cell lung cancer. Med Sci Monit. 2014 Dec 30;20:2830-6. doi: 10.12659/MSM.891318.
  51. Kawarada Y, Miyazaki M, Itoh A, Araki R, Iwamizu H, Kataoka T, Kumakura Y, Ota A, Nagai T, Yamada K. Incidence of and risk factors associated with nedaplatin-related hypersensitivity reactions. Int J Clin Oncol. 2017 Jun;22(3):593-599. doi: 10.1007/s10147-017-1091-4.